CARTESIAN THERAPEUTICS INCRNAC
ASignal's systematic analysis rates RNAC as Bearish.
Reflects the latest available analysis · analyzed Oct 11, 2026
The case on RNAC
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- High cash position with total cash of $147.61M
- Low debt-to-equity risk due to high cash balance
- Current ratio of 7.47x indicates strong liquidity
- Negative operating margin (-6679.69%)
- Negative free cash flow (-$47.48M)
- Negative enterprise value to EBITDA (-1.28x)
- Extremely high price-to-sales ratio (144.52x)
- Negative book value (PB ratio: -1.69x)
- MACD below signal line indicating bearish momentum
See the full verdict on RNAC
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RNAC
Most investors never get a second opinion, let alone several. ASignal runs RNAC past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.